liver disease

Novo Nordisk announced on Thursday that China's National Medical Products Administration approved Wegovy as the first GLP-1 receptor agonist indicated for the treatment of metabolic dysfunction-associated steatohepatitis, or MASH, in adult patients with moderate-to-severe liver fibrosis, opening a new front…